Matches in SemOpenAlex for { <https://semopenalex.org/work/W2246118158> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2246118158 endingPage "7116" @default.
- W2246118158 startingPage "7116" @default.
- W2246118158 abstract "7116 Background: P and G have well demonstrated, single-agent activity in pts with locally advanced or metastatic NSCLC. This phase II study was designed to determine the activity of the combination of PG when G was administered immediately prior to P on day 8 of a 21-day cycle. Methods: Pts with Stage IIIB/IV NSCLC were enrolled. Treatment was G 1250 mg/m 2 on D 1 and 8, with P 500 mg/m 2 on D 8, immediately following G. Treatment was repeated every 21 days for 6 cycles. Pts received folic acid, vitamin B12 and steroid prophylaxis. Results: 54 pts (32 M/22 F) were enrolled in the study. Median age was 65.0 (range = 43 - 87) years, ECOG PS 0: 1 = 35.2%: 57.4%; Stage IIIB (9.3%), Stage IV (90.7%); Histology: adeno (61.1%) squamous (18.5%), and large cell (5.6%). Median dose intensity was 83.2% for P and 82.2% for G. Grade 3 toxicities were neutropenia (12.0%), thrombocytopenia (8.0%), dyspnea (16.0%), febrile neutropenia (10.0%), anemia (4.0%), fatigue (18.0%), nausea (10.0%), vomiting (8.0%), and rash (2.0%). Grade 4 toxicities were neutropenia (28%), thrombocytopenia (4%), dyspnea (6%), anemia (0%), fatigue (4%), nausea (0%), vomiting (0%), rash (0%). Five patients (10%) experienced Grade 1 alopecia. Median TTPD was 4.4 months and survival was 10.6 months. There were 0 CR, 16 PR (35.6%), 16 SD (35.6%), and 12 PD (26.7%), for an overall best response rate of 35.6%. Conclusions: In this study, PG had a disease control rate (ORR + SD) of 71.1% in the front-line treatment of NSCLC, suggesting that this is an active doublet. Administering P on D 8 rather than D 1 did not seem to negatively impact the therapeutic index. [Table: see text]" @default.
- W2246118158 created "2016-06-24" @default.
- W2246118158 creator A5003839820 @default.
- W2246118158 creator A5007095503 @default.
- W2246118158 creator A5007830017 @default.
- W2246118158 creator A5016064449 @default.
- W2246118158 creator A5035640724 @default.
- W2246118158 creator A5035987792 @default.
- W2246118158 creator A5058286630 @default.
- W2246118158 date "2006-06-20" @default.
- W2246118158 modified "2023-09-23" @default.
- W2246118158 title "Front line therapy with gemcitabine(G) administered immediately prior to pemetrexed (P) for patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Final report of a phase II clinical trial" @default.
- W2246118158 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.7116" @default.
- W2246118158 hasPublicationYear "2006" @default.
- W2246118158 type Work @default.
- W2246118158 sameAs 2246118158 @default.
- W2246118158 citedByCount "2" @default.
- W2246118158 crossrefType "journal-article" @default.
- W2246118158 hasAuthorship W2246118158A5003839820 @default.
- W2246118158 hasAuthorship W2246118158A5007095503 @default.
- W2246118158 hasAuthorship W2246118158A5007830017 @default.
- W2246118158 hasAuthorship W2246118158A5016064449 @default.
- W2246118158 hasAuthorship W2246118158A5035640724 @default.
- W2246118158 hasAuthorship W2246118158A5035987792 @default.
- W2246118158 hasAuthorship W2246118158A5058286630 @default.
- W2246118158 hasConcept C121608353 @default.
- W2246118158 hasConcept C126322002 @default.
- W2246118158 hasConcept C141071460 @default.
- W2246118158 hasConcept C2776694085 @default.
- W2246118158 hasConcept C2777063308 @default.
- W2246118158 hasConcept C2777240266 @default.
- W2246118158 hasConcept C2778239845 @default.
- W2246118158 hasConcept C2778248108 @default.
- W2246118158 hasConcept C2778570526 @default.
- W2246118158 hasConcept C2778850193 @default.
- W2246118158 hasConcept C2780258809 @default.
- W2246118158 hasConcept C2780580376 @default.
- W2246118158 hasConcept C2780852908 @default.
- W2246118158 hasConcept C31760486 @default.
- W2246118158 hasConcept C71924100 @default.
- W2246118158 hasConcept C90924648 @default.
- W2246118158 hasConceptScore W2246118158C121608353 @default.
- W2246118158 hasConceptScore W2246118158C126322002 @default.
- W2246118158 hasConceptScore W2246118158C141071460 @default.
- W2246118158 hasConceptScore W2246118158C2776694085 @default.
- W2246118158 hasConceptScore W2246118158C2777063308 @default.
- W2246118158 hasConceptScore W2246118158C2777240266 @default.
- W2246118158 hasConceptScore W2246118158C2778239845 @default.
- W2246118158 hasConceptScore W2246118158C2778248108 @default.
- W2246118158 hasConceptScore W2246118158C2778570526 @default.
- W2246118158 hasConceptScore W2246118158C2778850193 @default.
- W2246118158 hasConceptScore W2246118158C2780258809 @default.
- W2246118158 hasConceptScore W2246118158C2780580376 @default.
- W2246118158 hasConceptScore W2246118158C2780852908 @default.
- W2246118158 hasConceptScore W2246118158C31760486 @default.
- W2246118158 hasConceptScore W2246118158C71924100 @default.
- W2246118158 hasConceptScore W2246118158C90924648 @default.
- W2246118158 hasIssue "18_suppl" @default.
- W2246118158 hasLocation W22461181581 @default.
- W2246118158 hasOpenAccess W2246118158 @default.
- W2246118158 hasPrimaryLocation W22461181581 @default.
- W2246118158 hasRelatedWork W1986752991 @default.
- W2246118158 hasRelatedWork W1988315133 @default.
- W2246118158 hasRelatedWork W1992718174 @default.
- W2246118158 hasRelatedWork W2006876985 @default.
- W2246118158 hasRelatedWork W2055141641 @default.
- W2246118158 hasRelatedWork W2063374291 @default.
- W2246118158 hasRelatedWork W2101702686 @default.
- W2246118158 hasRelatedWork W2138837920 @default.
- W2246118158 hasRelatedWork W2148434078 @default.
- W2246118158 hasRelatedWork W2157535063 @default.
- W2246118158 hasVolume "24" @default.
- W2246118158 isParatext "false" @default.
- W2246118158 isRetracted "false" @default.
- W2246118158 magId "2246118158" @default.
- W2246118158 workType "article" @default.